Orange Book

(redirected from Approved Drug Products with Therapeutic Equivalence Evaluations)
Also found in: Medical.

Orange Book

(security, standard)
A standard from the US Government National Computer Security Council (an arm of the U.S. National Security Agency), "Trusted Computer System Evaluation Criteria, DOD standard 5200.28-STD, December 1985" which defines criteria for trusted computer products. There are four levels, A, B, C, and D. Each level adds more features and requirements.

D is a non-secure system.

C1 requires user log-on, but allows group ID.

C2 requires individual log-on with password and an audit mechanism. (Most Unix implementations are roughly C1, and can be upgraded to about C2 without excessive pain).

Levels B and A provide mandatory control. Access is based on standard Department of Defense clearances.

B1 requires DOD clearance levels.

B2 guarantees the path between the user and the security system and provides assurances that the system can be tested and clearances cannot be downgraded.

B3 requires that the system is characterised by a mathematical model that must be viable.

A1 requires a system characterized by a mathematical model that can be proven.

See also crayola books, book titles.
References in periodicals archive ?
patent numbers 6,143,327 and 6,096,341) listed in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations database (commonly referred to as the Orange Book).
Food and Drug Administration's (FDA) Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book.
As directed by the Court, Bristol-Myers Squibb listed an ABI patent -- issued on August 1, 2000 -- covering a range of single unit dosage forms of paclitaxel in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book.
Federal Trade Commission (FTC) has concluded its inquiry regarding certain patent listings in the Food and Drug Administration's (FDA) Approved Drug Products with Therapeutic Equivalence Evaluations (also know as the FDA's Orange Book) for Teveten 600mg and Teveten HCT 600mg/12.
6,162,463 (the "'463 Patent") in the Food and Drug Administration's (FDA) Approved Drug Products With Therapeutic Equivalence Evaluations (commonly referred to as the "Orange Book") with respect to which Biovail had acquired exclusive rights.
The "FDA" refers to the United States Food and Drug Administration, and the "Orange Book" is officially known as the FDA's registry of Approved Drug Products with Therapeutic Equivalence Evaluations.
The "FDA" refers to the United States Food and Drug Administration, and the "Orange Book" is officially known as the FDA's list of Approved Drug Products with Therapeutic Equivalence Evaluations.
Biovail Corporation (NYSE:BVF) (TSE:BVF) today confirmed that the United States District Court - Southern District of Florida has formally announced the court's rejection of the Andrx Groups' (Nasdaq:ADRX) ("Andrx") application for an injunction to compel the FDA and/or Biovail to de-list Biovail's recently-listed patent ("the '463 patent") in the Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book.

Full browser ?